Abstract
Relapses are experienced by 85–90% of people at and following onset of multiple sclerosis, as a feature of their disease (Lublin and Reingold, 1996). There is a great deal of uncertainty and variation with regards to presentation, duration and frequency of recurrence of relapses which varies for each individual. Guidance from the National Institute for Health and Clinical Excellence (2003) recommend treating a relapse with high doses of methylprednisolone over a 3-5-day period. The evidence underpinning these recommendations as well as some of the theory and practice behind this will be reviewed in this article.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
